Oss Kantsingel site
Ardena’s New State-of-the-Art Nanomedicine Facility Secures Full GMP Approval for Manufacturing
19 nov. 2024 05h27 HE | Ardena Holding NV.
Ardena’s Oss facility secures GMP approval for nanomedicine manufacturing, enhancing capabilities in innovative drug development.
Roots-Analysis-Logo.png
Liposome development and liposome manufacturing services market is anticipated to grow at a CAGR of nearly 10% till 2035, claims Roots Analysis
02 févr. 2023 10h00 HE | Roots Analysis
London, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Roots Analysis has announced the addition of “Liposome Development and Liposome Manufacturing Services Market, 2022-2035” report to its list of offerings. ...
TIP_link_300x300.jpg
Ocular Drug Delivery Market Size to Outstrip $27,016.20Mn by 2028 Growth Projections at 7.4% CAGR During 2021 to 2028 COVID Impact and Global Analysis by TheInsightPartners.com
05 oct. 2021 11h00 HE | The Insight Partners
New York, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Ocular Drug Delivery Market: Key InsightsAccording to our new research study on "Ocular Drug Delivery Market to 2028 – Global Analysis and Forecast – by...
Plandaí Biotechnolog
Plandaí Biotechnology's Upcoming Clinical Trial Could Strengthen Case for Phytofare in Treatment of Diabetes
18 mai 2017 09h00 HE | Plandai Biotechnology, Inc.
NEW YORK, NY--(Marketwired - May 18, 2017) - Plandaí Biotechnology (OTCQB: PLPL) announced that it will conduct a human clinical trial to study the effectiveness of using its highly bioavailable...
Plandaí Biotechnolog
Plandaí Biotechnology Changing the Future of Green Tea with Technology Used in Origine 8 Capsules
10 mai 2017 09h00 HE | Plandai Biotechnology, Inc.
NEW YORK, NY--(Marketwired - May 10, 2017) - Plandaí Biotechnology's (OTCQB: PLPL) Origine 8™ capsules could be the future of green tea. Drinking a cup of green tea tastes great, but unless the eight...